| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
GPCR GPR120 FFAR4-412AP Blocking Peptide is synthetically produced from the 220-300 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
FFAR4 |
| Gene ID: |
338557 |
| Uniprot ID: |
FFAR4_HUMAN |
| Immunogen Region: |
220-300 |
| Immunogen: |
C-epitope synthetic peptide taken within amino acid region 220-300 on human FFAR4 protein. |
| Tissue Specificity | Isoform 2: The predominant isoform in human tissues. Expressed in adipose tissue, pancreatic islets, lung and brain. Expressed in alpha cells of pancreatic islets. Expressed in primary cilia of perivascular preadipocytes of white adipose tissue (at protein level). Abundant expression in the intestinal tract. Expressed in colonic intraepithelial neuroendocrine cells. |
| Post Translational Modifications | Phosphorylated at two clusters of Ser and Thr residues located in the intracellular C-terminus, a prerequisite for FFAR4 internalization via an ARRB2-dependent pathway. |
| Function | Isoform 2: G-protein-coupled receptor for long-chain fatty acids (LCFAs) with a major role in adipogenesis, energy metabolism and inflammation. Signals via G-protein and beta-arrestin pathways. LCFAs sensing initiates activation of phosphoinositidase C-linked G proteins GNAQ and GNA11 (G(q)/G(11)), inducing a variety of cellular responses via second messenger pathways such as intracellular calcium mobilization, modulation of cyclic adenosine monophosphate (cAMP) production, and mitogen-activated protein kinases (MAPKs). After LCFAs binding, associates with beta-arrestin ARRB2 that acts as an adapter protein coupling the receptor to specific downstream signaling pathways, as well as mediating receptor endocytosis. In response to dietary fats, plays an important role in the regulation of adipocyte proliferation and differentiation. Acts as a receptor for omega-3 polyunsaturated fatty acids (PUFAs) at primary cilium of perivascular preadipocytes, initiating an adipogenic program via cAMP and CTCF-dependent chromatin remodeling that ultimately results in transcriptional activation of adipogenic genes and cell cycle entry. Induces differentiation of brown adipocytes probably via autocrine and endocrine functions of FGF21 hormone. Activates brown adipocytes by initiating intracellular calcium signaling that leads to mitochondrial depolarization and fission, and overall increased mitochondrial respiration. Consequently stimulates fatty acid uptake and oxidation in mitochondria together with UCP1-mediated thermogenic respiration, eventually reducing fat mass. Regulates bi-potential differentiation of bone marrow mesenchymal stem cells toward osteoblasts or adipocytes likely by up-regulating distinct integrins. In response to dietary fats regulates hormone secretion and appetite. Stimulates GIP and GLP1 secretion from enteroendocrine cells as well as GCG secretion in pancreatic alpha cells, thereby playing a role in the regulation of blood glucose levels. Negatively regulates glucose-induced SST secretion in pancreatic delta cells. Mediates LCFAs inhibition of GHRL secretion, an appetite-controlling hormone. In taste buds, contributes to sensing of dietary fatty acids by the gustatory system. During the inflammatory response, promotes anti-inflammatory M2 macrophage differentiation in adipose tissue. Mediates the anti-inflammatory effects of omega-3 PUFAs via inhibition of NLRP3 inflammasome activation. In this pathway, interacts with adapter protein ARRB2 and inhibits the priming step triggered by Toll-like receptors (TLRs) at the level of TAK1 and TAB1. Further inhibits the activation step when ARRB2 directly associates with NLRP3, leading to inhibition of pro-inflammatory cytokine release. Mediates LCFAs anti-apoptotic effects. Isoform 1: Receptor for LCFAs decoupled from G-protein signaling. May signal through beta-arrestin pathway. After LCFAs binding, associates with beta-arrestin ARRB2 that may act as an adapter protein coupling the receptor to specific downstream signaling pathways, as well as mediating receptor endocytosis. |
| Peptide Name | Free Fatty Acid Receptor 4G-Protein Coupled Receptor 120G-Protein Coupled Receptor 129G-Protein Coupled Receptor Gt01G-Protein Coupled Receptor Pgr4Omega-3 Fatty Acid Receptor 1 |
| Database Links | Reactome: R-HSA-381771Reactome: R-HSA-416476Reactome: R-HSA-444209 |
| Cellular Localisation | Isoform 1: Cell MembraneMulti-Pass Membrane ProteinEndosome MembraneLysosome MembraneSorted To Late Endosome/Lysosome Compartments Upon InternalizationIsoform 2: Cell MembraneCell ProjectionCilium MembraneSpecifically Localizes To The Primary Cilium Of Undifferentiated AdipocytesCiliary Trafficking Is Tulp3-DependentAs The Cilium Is Lost During AdipogenesisMoves To The Plasma Membrane (Probable) |
| Alternative Peptide Names | Free Fatty Acid Receptor 4 proteinG-Protein Coupled Receptor 120 proteinG-Protein Coupled Receptor 129 proteinG-Protein Coupled Receptor Gt01 proteinG-Protein Coupled Receptor Pgr4 proteinOmega-3 Fatty Acid Receptor 1 proteinFFAR4 proteinGPR120 proteinGPR129 proteinO3FAR1 proteinPGR4 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
